STOCK TITAN

Cytek Biosciences, Inc. - CTKB STOCK NEWS

Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.

Cytek Biosciences, Inc. (CTKB) delivers advanced cell analysis solutions through its patented Full Spectrum Profiling technology, serving research institutions and biotech organizations worldwide. This page provides investors and industry professionals with direct access to official company announcements and relevant news updates.

Discover the latest developments including product innovations, financial results, strategic partnerships, and regulatory milestones. Our curated collection ensures you stay informed about CTKB’s progress in advancing high-resolution cellular analysis tools for scientific research.

Key updates cover earnings reports, technology enhancements, executive leadership changes, and market expansion initiatives. All content is sourced from verified channels to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Cytek Biosciences’ evolving story in life sciences innovation. Check back regularly for real-time updates that matter to stakeholders in the biotech investment community.

Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced it will report its second quarter 2024 financial results after market close on Tuesday, August 6, 2024. The company's management will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results, business developments, and outlook. Investors can access the live audio webcast on the company's website at investors.cytekbio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences earnings
-
Rhea-AI Summary

Cytek Biosciences announced a $50 million stock repurchase program, approved by its Board of Directors. This initiative aims to buy back shares of its common stock, listed under the Nasdaq symbol CTKB, up until December 31, 2024, unless modified. Repurchases will take place on the open market or through private transactions, adhering to SEC Rule 10b-18 and legal requirements. The program's extent and timing will depend on liquidity, cash flow, and market conditions. However, Cytek is not obliged to buy back any specific amount and may alter or suspend the program at any time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
buybacks
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB), a key player in cell analysis solutions, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL. Scheduled for June 12th at 9:20 a.m. Eastern Time, the company's management will engage in a fireside chat. The discussion will be accessible via a live and archived webcast on Cytek's investor relations webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences
Rhea-AI Summary

On May 28, 2024, Cytek Biosciences (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails received approval from China's National Medical Products Administration (NMPA) for clinical use. These reagents, used in the Cytek Northern Lights-Clinical (NL-CLC) cell analysis systems, aid in diagnosing and monitoring immune-related conditions such as immunodeficiencies, autoimmune diseases, infections, and cancers. The NMPA clearance marks the first clinical 1-laser based 6-color TBNK assay supported by Full Spectrum Profiling (FSP) capability. This approval enhances Cytek's market presence in China, offering new opportunities and strengthening its competitive edge. The Cytek NL-CLC systems are designed to perform optimally in multicolor environments, and their onboard volumetric meters reduce testing costs by eliminating the need for counting beads.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
none
-
Rhea-AI Summary

Cytek Biosciences has introduced the Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ and Cytek Northern Lights™ systems. This upgrade allows researchers to detect subcellular particles, such as extracellular vesicles (EVs), with superior sensitivity and resolution. The global EV market is projected to grow significantly, from $227.5 million in 2023 to $1.3 billion by 2028, at a CAGR of 42.2%. This advancement positions Cytek as a leader in the small particle research market. The ESP Detection Option enhances the study of viruses, bacteria, and nanoparticles, offering unprecedented light scatter sensitivity and enabling more accurate measurement and characterization of small particles.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
-
Rhea-AI Summary

Cytek Biosciences reported strong financial results for the first quarter of 2024, with total revenue reaching $44.9 million, a 21% increase from the previous year. The company's organic revenue saw a significant 11% growth, driven by the acquisition of product lines from Luminex Cytek also expanded its operations by opening a new facility in China and received approval for a TBNK panel. Despite a decrease in gross profit margin, the company remains focused on sustainable growth and profitability. Cytek reaffirmed its revenue guidance for 2024, expecting a positive net income for the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
Rhea-AI Summary

Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its Full Spectrum Profiling™ (FSP™) technology at CYTO 2024 and AAI’s IMMUNOLOGY2024. The company offers cell analysis solutions for various fields like immunology and oncology. They will conduct educational workshops, tutorials, and exhibit their suite of instruments, reagents, software, and services at these conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
conferences
-
Rhea-AI Summary

Cytek Biosciences, Inc. (Nasdaq: CTKB) will report its first quarter 2024 financial results on May 8, 2024. The management will hold a conference call to discuss the results, business developments, and outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
conferences earnings
-
Rhea-AI Summary
Cytek Biosciences, Inc. appoints William McCombe as CFO, reaffirms 2024 revenue guidance of $203 million to $213 million with expected positive net income. McCombe brings extensive experience from leading technology companies and investment banking, positioning Cytek for sustainable growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
Rhea-AI Summary
Cytek Biosciences, Inc. (CTKB) expands its manufacturing capacity with a new facility in Wuxi, China, to meet the increasing demand for cell analysis solutions worldwide. The facility enables unique vendor relationships and in-house component manufacturing, enhancing Cytek's position in the industry. Cytek's product portfolio includes innovative cell analyzers and sorters, empowering scientists with advanced technology for research in various fields like immuno-oncology and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
Cytek Biosciences, Inc.

Nasdaq:CTKB

CTKB Rankings

CTKB Stock Data

473.96M
116.54M
8.9%
61.33%
2.69%
Medical Devices
Laboratory Analytical Instruments
Link
United States
FREMONT